Skip to main content

Table 1 Baseline patient characteristics among all three adjuvant NY-ESO-1 clinical trials

From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

  NCT00821652 NCT01079741 NCT00124124  
  N = 22 N = 35 N = 34  
  N(%)/Mean(SD) N(%)/Mean(SD) N(%)/Mean(SD) P-Value
Age 59.68 (13.60) 55.49 (15.16) 56.38 (11.82) 0.5134
Sex     0.2446
 Female 9 (40.91) 14 (40.00) 20 (58.82)  
 Male 13 (59.09) 21 (60.00) 14 (41.18)  
Thicknessa 2.63 (1.64) 2.22 (1.84) 4.48 (5.63) 0.0122
Ulceration     0.1916
 Present 7 (31.82) 11 (31.43) 18 (52.94)  
 Absent 10 (45.45) 17 (48.57) 14 (41.18)  
 Undetermined 5 (22.73) 7 (20.00) 2 (5.88)  
AJCC Stage     0.0146
 IIB 0 (0.00) 3 (8.57) 7 (20.59)  
 IIC 1 (4.55) 1 (2.86) 0 (0.00)  
 IIIA 5 (22.73) 4 (11.43) 6 (17.65)  
 IIIB 5 (22.73) 11 (31.43) 10 (29.41)  
 IIIC 4 (18.18) 12 (34.29) 10 (29.41)  
 IV 7 (31.82) 4 (11.43) 0 (0.00)  
 Undetermined 0 (0.00) 0 (0.00) 1 (2.94)  
Histologic Subtype     0.5588
 Nodular 6 (27.27) 7 (20.00) 12 (35.29)  
 Superficial Spreading 4 (18.18) 5 (14.29) 7 (20.59)  
 Other 3 (13.64) 2 (5.71) 4 (11.76)  
 Undetermined 9 (40.91) 21 (60.00) 11 (32.35)  
Primary site     0.2624
 Anterior Trunk 0 (0.00) 4 (11.43) 6 (17.65)  
 Arms 3 (13.64) 5 (14.29) 1 (2.94)  
 Head/Neck 5 (22.73) 3 (8.57) 6 (17.65)  
 Legs 8 (36.36) 15 (42.86) 12 (35.29)  
 Posterior Trunk 3 (13.64) 6 (17.14) 8 (23.53)  
 Unknown 3 (13.64) 2 (5.71) 1 (2.94)  
  1. amissing values for thickness: NCT00821652: 4; NCT01079741: 5;NCT00124124: 1